Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 9/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 9/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 9/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.38 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | YAP1 | P46937 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24322050 | 0.84 | TAS1R3 (0.40) | NPC1RAB9ATAS1R3TAS1R1TAS1R2 | |
| SCHEMBL10713709 | 0.77 | MAPK8 (0.52) | MAPK8MAPK9MAPK10MAPTALDH1A1 | |
| SCHEMBL24322959 | 0.76 | MAPK8 (0.49) | MAPK8MAPK9MAPK10MAPTALDH1A1 | |
| SCHEMBL19994051 | 0.73 | RAB9A (0.50) | MAPK8MAPK9MAPK10SMN1; SMN2NPC1 | |
| SCHEMBL9852547 | 0.73 | ALDH1A1 (0.50) | MAPK8MAPK9MAPK10SMN1; SMN2MAPT | |
| SCHEMBL20014303 | 0.72 | RAB9A (0.49) | SMN1; SMN2NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL31392463 | 0.72 | MAPK8 (0.54) | MAPK8MAPK9MAPK10SMN1; SMN2NPC1 | |
| SCHEMBL13861476 | 0.71 | MAPT (0.61) | MAPK8MAPK9MAPK10SMN1; SMN2MAPT | |
| SCHEMBL19993983 | 0.71 | RAB9A (0.47) | MAPK8MAPK9MAPK10SMN1; SMN2NPC1 | |
| SCHEMBL11579947 | 0.69 | MAPK8 (0.45) | MAPK8MAPK9MAPK10MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357265-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2023-11-09 | — | — | US | disclosed |
| US-20230357265-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2023-11-09 | — | — | US | disclosed |
| US-20230357265-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2023-11-09 | — | — | US | disclosed |
| CN-116583283-A | CDK inhibitors and their use as pharmaceuticals | 普莱鲁德疗法有限公司 | 2023-08-11 | — | — | CN | disclosed |
| EP-4214213-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | Prelude Therapeutics, Incorporated (US) | 2023-07-26 | — | — | EP | disclosed |
| US-11685744-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685744-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685744-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-06-27 | — | — | US | disclosed |
| WO-2022061273-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2022-03-24 | — | — | WO | disclosed |
| WO-2022061273-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2022-03-24 | — | — | WO | disclosed |
| US-20220089608-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089608-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK1, CDK3 | MAPK8 228/4885MAPK9 137/4885MAPK10 246/4885 |
| US-20230357265-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK1, CDK3 | MAPK8 228/4885MAPK9 137/4885MAPK10 246/4885 |
| US-11685744-B2 | CDK inhibitors and their use as pharmaceuticals | CDK6, CDK1, CDK3 | MAPK8 228/4885MAPK9 137/4885MAPK10 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.